Health economic assessment of Qarziba in patients with high-risk neuroblastoma

TLV

21 April 2021 - TLV has produced a health economic assessment for the regions for the drug Qarziba (dinutuximab beta). 

TLV has evaluated Qarziba as the first-line treatment for so-called high-risk neuroblastoma in patients aged 12 months and older.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder